Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Large Differences between Focal and Diffuse Patterns of Stable CAD

PCI is far more successful at reducing ischemia when treating focal stable coronary artery disease (CAD). However, there were no differences in symptoms between both types of CAD. 

Grandes diferencias entre angioplastia en enfermedad focal vs difusa

Physiological assessment with pressure wire pullback can be used to distinguish focal vs diffuse CAD, even though the relevance of this distinction has not been looked at closely. 

Using the ORBITA database, researchers tested PCI efficacy against placebo in both types of CAD patterns (focal vs diffuse). They observed the impact of these patterns on stress echocardiography ischemia and symptom end points. 

164 patients were assessed with iFR pullback before randomization. Focal CAD was defined as iFR drop >0.03 within 15 mm. Greater distances were defined as diffuse CAD. 

Of the 85 patients in the ORBITA PCI branch, 48 showed focal lesions and 37 diffuse CAD. IN the placebo arm (n=79) 35 had focal lesions and 44 diffuse CAD.

Focal stenosis was associated with significantly lower FFR and iFR vs. diffuse pattern patients (mean FFR and iFR, focal 0.60±0.15 and 0.65±0.24, diffuse 0.78±0.10 and 0.88±0.08, respectively, p<0.0001).


Read also: New Markers of Aortic Stenosis Define Asymptomatic Patients.


Stress echocardiography ischemia saw significantly greater reduction with PCI when patients showed a focal pattern, vs. a diffuse pattern (p<0.05). 

PCI did not show significant variation in exercise time pre and post randomization. This continued to be true after stratifying patients according to CAD pattern. 

PCI was superior to placebo when using the Seattle Angina Questionnaire both in frequency and freedom from symptoms. However, these differences continued to be true and similar when stratifying patients into focal and diffuse CAD. 

Conclusion

PCI achieve greater ischemia reduction with focal CAD vs. diffuse. There were no differences in symptom end points. 

CIRCINTERVENTIONS-120-009891

Original Title: Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease.

Reference: Christopher A Rajkumar et al. Circ Cardiovasc Interv. 2021 Aug 3;CIRCINTERVENTIONS120009891. Online ahead of print. doi: 10.1161/CIRCINTERVENTIONS.120.009891.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...